These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Significance and progress of DIAN/A4/API]. Shimada H Nihon Rinsho; 2016 Mar; 74(3):417-22. PubMed ID: 27025079 [TBL] [Abstract][Full Text] [Related]
10. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Wang G; Berry S; Xiong C; Hassenstab J; Quintana M; McDade EM; Delmar P; Vestrucci M; Sethuraman G; Bateman RJ; Stat Med; 2018 Sep; 37(21):3047-3055. PubMed ID: 29761523 [TBL] [Abstract][Full Text] [Related]
11. Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease? Imbimbo BP; Lucca U; Watling M Neurol Genet; 2021 Feb; 7(1):e535. PubMed ID: 33575481 [TBL] [Abstract][Full Text] [Related]
12. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. Aisen PS; Bateman RJ; Carrillo M; Doody R; Johnson K; Sims JR; Sperling R; Vellas B J Prev Alzheimers Dis; 2021; 8(3):306-312. PubMed ID: 34101788 [TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN). McKay NS; Gordon BA; Hornbeck RC; Dincer A; Flores S; Keefe SJ; Joseph-Mathurin N; Jack CR; Koeppe R; Millar PR; Ances BM; Chen CD; Daniels A; Hobbs DA; Jackson K; Koudelis D; Massoumzadeh P; McCullough A; Nickels ML; Rahmani F; Swisher L; Wang Q; Allegri RF; Berman SB; Brickman AM; Brooks WS; Cash DM; Chhatwal JP; Day GS; Farlow MR; la Fougère C; Fox NC; Fulham M; Ghetti B; Graff-Radford N; Ikeuchi T; Klunk W; Lee JH; Levin J; Martins R; Masters CL; McConathy J; Mori H; Noble JM; Reischl G; Rowe C; Salloway S; Sanchez-Valle R; Schofield PR; Shimada H; Shoji M; Su Y; Suzuki K; Vöglein J; Yakushev I; Cruchaga C; Hassenstab J; Karch C; McDade E; Perrin RJ; Xiong C; Morris JC; Bateman RJ; Benzinger TLS; Nat Neurosci; 2023 Aug; 26(8):1449-1460. PubMed ID: 37429916 [TBL] [Abstract][Full Text] [Related]
14. Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease. Wang G; Li Y; Xiong C; Benzinger TLS; Gordon BA; Hassenstab J; Aschenbrenner AJ; McDade E; Clifford DB; Libre-Guerra JJ; Shi X; Mummery CJ; van Dyck CH; Lah JJ; Honig LS; Day G; Ringman JM; Brooks WS; Fox NC; Suzuki K; Levin J; Jucker M; Delmar P; Bittner T; Bateman RJ; Alzheimers Dement; 2024 Apr; 20(4):2698-2706. PubMed ID: 38400532 [TBL] [Abstract][Full Text] [Related]
15. The role of the Alzheimer's Disease Neuroimaging Initiative in establishing the Dominantly Inherited Alzheimer Network. Morris JC; Buckles VD Alzheimers Dement; 2024 Aug; 20(8):5789-5791. PubMed ID: 38958563 [TBL] [Abstract][Full Text] [Related]